In short
Cabozantinib is an innovative drug being studied in various clinical trials for its potential to treat multiple types of cancer. This article explores the ongoing research into cabozantinib's effectiveness and safety across different cancer types, including renal cell carcinoma, prostate cancer, and other solid tumors. We'll examine the key findings from recent clinical trials and what they mean for patients and the future of cancer treatment.
At a glance
- Main Cancer Types Studied
- Renal Cell Carcinoma, Prostate Cancer, Non-Small Cell Lung Cancer, Urothelial Carcinoma
- Common Dosages
- 20 mg, 40 mg, 60 mg daily
- Administration
- Oral tablets, taken once daily
- Primary Outcome Measures
- Progression-Free Survival, Objective Response Rate, Maximum Tolerated Dose
- Secondary Outcome Measures
- Overall Survival, Duration of Response, Safety and Tolerability
- Combination Therapies
- Often studied in combination with immunotherapy drugs (e.g., atezolizumab)
- Trial Phases
- Phase 1, Phase 2, and Phase 3 studies ongoing
- Patient Populations
- Both treatment-naive and previously treated patients, depending on the study
- Safety Monitoring
- Regular assessment of adverse events, using criteria such as CTCAE v4.0 or v5.0
- Biomarker Studies
- Some trials include analysis of biomarkers to predict or monitor treatment response
What is Cabozantinib?
Cabozantinib is a medication used to treat various types of cancer. It's also known by several other names, including XL184, Cometriq, Cabometyx, and BMS907351. This drug is part of a class of medications called tyrosine kinase inhibitors, which work by targeting specific proteins in cancer cells to slow down or stop their growth.
How Does Cabozantinib Work?
Cabozantinib works by inhibiting several proteins that are involved in cancer growth and spread. Specifically, it targets proteins called RET, ROS1, NTRK, MET, and AXL. By blocking these proteins, cabozantinib can:
- Slow down or stop cancer cell growth
- Prevent the formation of new blood vessels that feed tumors (a process called angiogenesis)
- Reduce the spread of cancer to other parts of the body (metastasis)
Conditions Treated with Cabozantinib
Cabozantinib has been studied and used to treat several types of cancer, including:
- Advanced or metastatic renal cell carcinoma (kidney cancer)
- Non-small cell lung cancer, especially in patients with specific genetic changes like RET, ROS1, or NTRK fusions
- Medullary thyroid cancer
- Advanced or metastatic cervical cancer
- Pancreatic cancer
- Multiple myeloma (a type of blood cancer)
- Meningioma (a type of brain tumor)
- Plexiform neurofibromas in patients with neurofibromatosis type 1 (NF1)
How is Cabozantinib Administered?
Cabozantinib is typically taken orally (by mouth) in the form of tablets or capsules. The dosage and schedule can vary depending on the specific condition being treated and the patient's individual needs. Some common dosing regimens include:
- 60 mg once daily
- 40 mg once daily, with potential escalation to 60 mg based on tolerability
- Dosing based on body surface area for children (e.g., 30 mg/m2/day)
Treatment cycles are often 28 days long, and patients may continue taking cabozantinib as long as they are benefiting from it and not experiencing severe side effects.
Ongoing Clinical Trials
Cabozantinib is currently being studied in various clinical trials to determine its effectiveness in treating different types of cancer and to explore new combinations with other treatments. Some ongoing studies include:
- Combining cabozantinib with immunotherapy drugs for kidney cancer
- Using cabozantinib in combination with chemotherapy drugs like gemcitabine for pancreatic cancer
- Evaluating cabozantinib's effectiveness in treating plexiform neurofibromas in children and adults with NF1
Potential Side Effects
Like all medications, cabozantinib can cause side effects. Common side effects may include:
- Fatigue
- Diarrhea
- Nausea
- Decreased appetite
- Hand-foot syndrome (redness, swelling, and pain on the palms of hands and soles of feet)
- High blood pressure
More serious side effects, though less common, can include:
- Bleeding problems
- Wound healing complications
- Liver problems
- Blood clots
Patients taking cabozantinib are closely monitored by their healthcare team for any side effects, and the dose may be adjusted if necessary.